Results 111 to 120 of about 73,261,523 (214)

Poster Session 2

open access: yes
Pregnancy, Volume 2, Issue S2, September 2026.
wiley   +1 more source

Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM? [PDF]

open access: yesPLoS One, 2022
Cohen G   +9 more
europepmc   +1 more source

Poster Session 4

open access: yes
Pregnancy, Volume 2, Issue S2, September 2026.
wiley   +1 more source

Diurnal salivary androstenedione and 17-hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia. [PDF]

open access: yesClin Endocrinol (Oxf), 2022
Adriaansen BPH   +11 more
europepmc   +1 more source

Salivary 17-hydroxyprogesterone (17-OHP) and androstenedione in monitoring efficacy of treatment among Indonesian Congenital Adrenal Hyperplasia Patients

open access: yesJournal of the ASEAN Federation of Endocrine Societies, 2014
Objective.  Early diagnosis of congenital adrenal hyperplasia (CAH) and the need for long term treatment are of great concern to the medical community. The aim of this study was to evaluate the effectiveness of glucocorticoid treatment-monitoring based ...
Achmad Zulfa Juniarto   +7 more
doaj  

A 4-hour Profile of 17-hydroxyprogesterone in Salt-wasting Congenital Adrenal Hyperplasia: Is the Serial Monitoring Strategy Worth the Effort? [PDF]

open access: yesJ Clin Res Pediatr Endocrinol, 2022
Besci Ö   +6 more
europepmc   +1 more source

Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.

open access: yes, 2020
Background: Progesterone has been used for preventing preterm birth with mixed results. The American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine recommended the use of 17-hydroxyprogesterone caproate for risk ...
Mikovich, Sam   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy